|
Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis
orders such as Alzheimer’s disease and proliferative diseases such as renal diseases and cancers. These observations led the CDK family to become a central target for the development of new therapies.
During the last two decades, evolution of patent filings of CDK inhibit
ors shows two major phases. A strong increase until 2002 is associated with the capacity of CDK inhibitors to target a large number of diseases. Results of advanced clinical stages confirm the potential of these compounds but emphasize new challenges in
order to reach marketable products. A significant decrease follows until 2005 when a new generation of CDK inhibitors takes the lead in R&D interest.
This IP Overview provides you with a comprehensive panorama of the intellectual property landscape of this new and promising sector and helps you:
- Position your company’s R&D and IP Portfolio,
- Identify key inventors and key players involved in specific thematic,
- Understand the collaboration networks and theirs dynamics,
- Uncover trends and emerging segments. |
